Calvin Cao serves as Executive at Stem Cell Therapy International, Inc., where they oversee executive responsibilities. Since joining the company, Calvin Cao has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jun 27, 2022 involved exercising options for 51,507,749 shares valued at $0.
Calvin Cao currently holds 51,507,749 shares of Stem Cell Therapy International, Inc. (SCII), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Calvin Cao has been a net neutral trader of SCII stock. They have purchased $0 and sold $0 worth of shares.
Calvin Cao's most recent insider trade was on Jun 27, 2022, when they sold 51,507,749 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |